Myriad Genetics, Inc. (NASDAQ:MYGN)’s share price traded up 0.8% on Thursday . The company traded as high as $33.20 and last traded at $32.82. 811,478 shares were traded during mid-day trading, a decline of 26% from the average session volume of 1,090,590 shares. The stock had previously closed at $32.57.

A number of equities analysts have weighed in on the stock. Deutsche Bank AG raised shares of Myriad Genetics from a “sell” rating to a “hold” rating and decreased their price objective for the company from $27.86 to $15.00 in a research report on Friday, August 18th. Cowen and Company reissued a “hold” rating and issued a $25.00 price objective on shares of Myriad Genetics in a research report on Monday, August 14th. BidaskClub raised shares of Myriad Genetics from a “hold” rating to a “buy” rating in a research report on Saturday, August 12th. Zacks Investment Research cut shares of Myriad Genetics from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $23.00 price objective (up from $21.00) on shares of Myriad Genetics in a research report on Thursday, August 10th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $21.22.

The company has a market cap of $2.23 billion, a price-to-earnings ratio of 101.97 and a beta of 0.26. The company has a 50-day moving average of $27.51 and a 200 day moving average of $22.74.

Myriad Genetics (NASDAQ:MYGN) last announced its earnings results on Tuesday, August 8th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.26 by $0.04. The firm had revenue of $200.50 million for the quarter, compared to the consensus estimate of $193.71 million. Myriad Genetics had a net margin of 2.83% and a return on equity of 9.67%. The business’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.36 EPS. Equities analysts forecast that Myriad Genetics, Inc. will post $1.02 EPS for the current fiscal year.

In other Myriad Genetics news, Director John T. Henderson sold 30,000 shares of the firm’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $30.30, for a total value of $909,000.00. Following the sale, the director now directly owns 52,524 shares in the company, valued at approximately $1,591,477.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 6.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of MYGN. BlackRock Inc. grew its position in Myriad Genetics by 168,335.7% in the 1st quarter. BlackRock Inc. now owns 9,541,884 shares of the company’s stock worth $183,203,000 after purchasing an additional 9,536,219 shares during the last quarter. Thrivent Financial For Lutherans grew its position in Myriad Genetics by 7,026.7% in the 2nd quarter. Thrivent Financial For Lutherans now owns 2,742,340 shares of the company’s stock worth $70,862,000 after purchasing an additional 2,703,860 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Myriad Genetics by 59.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,642,820 shares of the company’s stock worth $50,742,000 after purchasing an additional 987,966 shares during the last quarter. Vanguard Group Inc. grew its position in Myriad Genetics by 16.8% in the 1st quarter. Vanguard Group Inc. now owns 6,251,030 shares of the company’s stock worth $120,020,000 after purchasing an additional 897,287 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in Myriad Genetics by 131.2% in the 1st quarter. Bank of New York Mellon Corp now owns 918,305 shares of the company’s stock worth $17,632,000 after purchasing an additional 521,146 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: “Myriad Genetics, Inc. (MYGN) Trading Up 0.8%” was published by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://www.dailypolitical.com/2017/09/09/myriad-genetics-inc-mygn-trading-up-0-8.html.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.